Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Pergolide mesilate
Genus Pharmaceuticals Ltd
N04BC02
Pergolide mesilate
1mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04090100
s $/./4CRUSHPERGOLIDETABLETSBECAUSETHEYCAN CAUSEEYEIRRITATIONIRRITATINGSMELLORHEADACHE CHILDREN AND ADOLESCENTS 0ERGOLIDEISNOTRECOMMENDEDFORUSEINCHILDRENAND ADOLESCENTS OTHER MEDICINES AND PERGOLIDE TELL YOUR DOCTOR OR PHARMACIST IF YOU ARE TAKING, HAVE RECENTLY TAKEN OR MIGHT TAKE ANY OTHER MEDICINES. ESPECIALLY TALK TO YOUR DOCTOR IF YOU ARE TAKING ANY OF THE FOLLOWING: s , DOPALEVODOPAALSOUSEDINTHETREATMENTOF 0ARKINSONSDISEASE/CCASIONALLYMOVEMENT DISORDERCONFUSIONANDHALLUCINATIONSHAVEBEEN CAUSEDORMADEWORSEBY0ERGOLIDEANDLEVODOPA BEINGTAKENTOGETHER s WARFARINAMEDICINEWHICHSTOPSYOURBLOOD CLOTTINGASTHEDOSAGEOFEITHERMEDICINEMAY NEEDTOBEREDUCED s MEDICINESFORHIGHBLOODPRESSUREAS0ERGOLIDE MAYALSOCAUSEALOWERINGOFBLOODPRESSURE s MEDICINESTOSTOPYOUFEELINGSICKEG METOCLOPRAMIDEORPROCHLORPERAZINE4HESE MEDICINESMAYREDUCETHEEFFECTOFPERGOLIDE)F YOUFEELSICKATTHESTARTOFTHERAPYYOUMUST CONSULTYOURDOCTORORPHARMACISTBEFORETAKING ANTI SICKNESSMEDICATIONWITH0ERGOLIDE4ABLETS s ANYMEDICINESUSEDTOTREATMENTALHEALTH CONDITIONSPARTICULARLYNEUROLEPTICMEDICINES PHENOTHIAZINESSUCHASCHLORPROMAZINE PROCHLORPERAZINEBUTYROPHENONESSUCHAS HALOPERIDOLBENPERIDOLTHIOXANTHENESSUCHAS FLUPENTIXOLZUCLOPENTHIXOL s RYEERGOTALKALOIDSEGERGOTAMINE DIHYDROERGOTAMINEMETHYLERGOTAMINE s MACROLIDEANTIBIOTICSEGAZITHROMYCIN CLARITHROMYCINERYTHROMYCIN s DRUGSTHATMIMICTHESYMPATHETICNERVOUSSYSTEM ANDSTIMULATEALPHASUBTYPEOFRECEPTORSEG EPHEDRINEMETHYLDOPA s ANYMEDICINEFORTREATINGPLASMAPROTEINSINYOUR BODY $ONOTSTOPTAKINGOTHERMEDICINESYOUHAVEALREADY BEENPRESCRIBEDBYYOURDOCTORWITHOUTTALKINGTOYOUR DOCTORFIRST PREGNANCY AND BREAST-FEEDING s 9OUMUSTNOTTAKEPERGOLIDEIFYOUAREPREGNANTOR BREAST FEEDING s )FYOUAREPREGNANTPLANNINGTOBECOMEPREGNANTOR AREBREAST FEEDINGASKYOURDOCTORFORADVICEBEFORE TAKINGANYMEDICINE DRIVING AND USING MACHINES s 0ERGOLIDEMAYMAKEYOUFEELDROWSYORCAUSEYOUTO FALLASLEEPSUDDENLYSOMETIMESWITHOUTWARNING)F YOUAREAFFECTED$/./4DRIVEOROPERATEMACHINERY HOW TO TAKE PERGOLIDE !LWAYSTAKE0ERGOLIDEEXACTLYASYOURDOCTORHASTOLD YOU Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Pergolide 1 milligram Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains, as the active ingredient, pergolide mesilate equivalent to 1 milligram of pergolide. 3. PHARMACEUTICAL FORM Tablet: light pink, rectangular shaped, scored, marked ‘G’. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Second-line therapy of Parkinson’s disease, or as adjunctive treatment to levodopa, when treatment with dopamine agonist is considered and when non-ergot alkaloids are contraindicated or are no longer adequate. The treatment should be initiated under specialist supervision. The benefit of continuing treatment should be regularly reassessed taking into account the risk of fibrotic reactions and valvulopathy (see sections 4.3, 4.4 and 4.8). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral administration to adults only. _Monotherapy _ The following titration should be used for initiation of pergolide as monotherapy: Day Morning Noon Evening Total Dosage 1 - - 50 micrograms 50 micrograms 2 – 4 - 50 micrograms 50 micrograms 100 micrograms 5 – 7 50 micrograms 50 micrograms 100 micrograms 200 micrograms 8 – 10 100 micrograms 100 micrograms 100 micrograms 300 micrograms 11 – 13 100 micrograms 150 micrograms 150 micrograms 400 micrograms 14 – 17 200 micrograms 200 micrograms 200 micrograms 600 micrograms 18 – 21 250 micrograms 250 micrograms 250 micrograms 750 micrograms 22 – 24 500 micrograms 250 micrograms 250 micrograms 1000 micrograms 25 – 27 500 micrograms 500 micrograms 250 micrograms 1250 micrograms 28 – 30 500 micrograms 500 micrograms 500 micrograms 1500 micrograms After day 30, the daily dose should be increased by at most 250 micrograms twice a week until an optimal therapeutic response is achieved. Pergolide mesilate is usually administered in divided doses 3 times per day. In clinical studies of pergolide as monotherapy, the mean dose was 2100 micrograms per day at 3 months and 2510 micrograms per day at 1 ye Read the complete document